Stellar Biotechnologies, Inc.
Stellar Biotechnologies Listed on Frankfurt Stock Exchange
Stellar Biotechnologies, Inc. / Key word(s): IPO Stellar Biotechnologies Listed on Frankfurt Stock Exchange PORT HUENEME, CA USA–(February 28, 2012)- Stellar Biotechnologies, Inc. ('Stellar') (TSX-V: KLH.V – News) (Pinksheets: SBOTF.PK – News) (FSE: RBT.F) is pleased to announce that it has recently listed on the Frankfurt Stock Exchange (FSE), and will trade under the symbol RBT.F (WKN A1C5EH). Stellar is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). 'We are pleased to be listed on the Frankfurt Stock Exchange,' said Mr. Frank Oakes, President and CEO of Stellar Biotechnologies. 'As a forward-thinking company, we are among an increasing number of U.S. companies focused on expanding our reach in Europe. This new listing will benefit both Stellar and our shareholders alike as we look to broaden our shareholder base and awareness in Germany and Europe.' KLH is sourced from a limited natural resource, and Stellar is the only company in the world that has turned this limited natural resource into a renewable one, Mr. Darrell Brookstein, EVP of Corporate Development & Finance said, 'As new applications are developed and demand for pharmaceutical grade KLH increases, only Stellar is in a position to meet demand.' Brookstein added, 'I believe the cross-border listing increases liquidity options and creates new strategic partnership opportunities for Stellar.' About Stellar Stellar Biotechnologies, Inc. (TSX-V: KLH.V – News) (Pinksheets: SBOTF.PK – News) (FSE: RBT.F) (www.StellarBiotechnologies.com) is the world leader in sustainable manufacturing of pharmaceutical grade KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the growing demand for renewable, commercial-scale supplies of high-quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need. To receive regular updates, enter email at bottom ofhttp://stellarbiotechnologies.com/investors/news_releases/. Stellar Contact:
Contact for Stellar Biotechnologies, Inc. Contacts for IR/PR
TheBiotechPanel, Inc.: There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases. End of Corporate News 28.02.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
158372 28.02.2012 |